Reply to: Beyond S100B: The need for new biomarkers in stage III melanoma recurrence detection

Affiliations

• ¹ University of Groningen, University Medical Center Groningen (UMCG), Department of Surgical Oncology, Hanzeplein 1, 9700 RB, Groningen, the Netherlands; University of Parma, Parma University Hospital, Department of Medicine and Surgery, Via Gramsci 14, 43100, Parma, Italy; Institute of Romagna for the Study of Cancer (IRST IRCSS), Skin Cancer Unit, 47014, Meldola, Italy. Electronic address: [email protected].
• ² Institute for Cancer Research, Prevention, and Clinical Network (ISPRO), Cancer Risk Factors and Lifestyle Epidemiology Unit, 50139, Florence, Italy. Electronic address: [email protected].
• ³ University of Parma, Parma University Hospital, Department of Medicine and Surgery, Via Gramsci 14, 43100, Parma, Italy; Institute of Romagna for the Study of Cancer (IRST IRCSS), Skin Cancer Unit, 47014, Meldola, Italy. Electronic address: [email protected].
• ⁴ University of Groningen, University Medical Center Groningen (UMCG), Department of Surgical Oncology, Hanzeplein 1, 9700 RB, Groningen, the Netherlands. Electronic address: [email protected].
• ⁵ University of Groningen, University Medical Center Groningen (UMCG), Department of Surgical Oncology, Hanzeplein 1, 9700 RB, Groningen, the Netherlands. Electronic address: [email protected].